APA (7th ed.) Citation

AS, M., Z, W., R, M., AT, S., CH, L., PM, F., . . . KT, F. (2022). Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. NPJ precision oncology, 6(1), 13. https://doi.org/10.1038/s41698-022-00256-w

Chicago Style (17th ed.) Citation

AS, Mansfield, et al. "Crizotinib in Patients with Tumors Harboring ALK or ROS1 Rearrangements in the NCI-MATCH Trial." NPJ Precision Oncology 6, no. 1 (2022): 13. https://doi.org/10.1038/s41698-022-00256-w.

MLA (9th ed.) Citation

AS, Mansfield, et al. "Crizotinib in Patients with Tumors Harboring ALK or ROS1 Rearrangements in the NCI-MATCH Trial." NPJ Precision Oncology, vol. 6, no. 1, 2022, p. 13, https://doi.org/10.1038/s41698-022-00256-w.